|
[1]
|
Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research
BMJ Open,
2023
DOI:10.1136/bmjopen-2021-059288
|
|
|
|
|
[2]
|
Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia
Frontiers in Oncology,
2023
DOI:10.3389/fonc.2023.1160966
|
|
|
|
|
[3]
|
Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
The Breast,
2023
DOI:10.1016/j.breast.2023.103588
|
|
|
|
|
[4]
|
The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients
Drugs & Therapy Perspectives,
2023
DOI:10.1007/s40267-023-01038-5
|
|
|
|
|
[5]
|
Costos de la administración intravenosa vs. subcutánea del trastuzumab en pacientes peruanas con cáncer de mama HER2 positivo. Un análisis observacional de los costos directos e indirectos
Journal of Healthcare Quality Research,
2022
DOI:10.1016/j.jhqr.2021.10.008
|
|
|
|
|
[6]
|
Formulation and Device Lifecycle Management of Biotherapeutics
2022
DOI:10.1016/B978-0-12-823741-0.00002-6
|
|
|
|
|
[7]
|
White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
Advances in Therapy,
2022
DOI:10.1007/s12325-021-01996-0
|
|
|
|
|
[8]
|
Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England
ClinicoEconomics and Outcomes Research,
2022
DOI:10.2147/CEOR.S360741
|
|
|
|
|
[9]
|
An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
European Journal of Breast Health,
2022
DOI:10.4274/ejbh.galenos.2021.2021-9-9
|
|
|
|
|
[10]
|
Drug Delivery Devices and Therapeutic Systems
2021
DOI:10.1016/B978-0-12-819838-4.00021-3
|
|
|
|
|
[11]
|
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
BioDrugs,
2021
DOI:10.1007/s40259-020-00461-8
|
|
|
|
|
[12]
|
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
British Journal of Cancer,
2021
DOI:10.1038/s41416-020-01255-z
|
|
|
|
|
[13]
|
Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Clinical Pharmacology in Drug Development,
2021
DOI:10.1002/cpdd.936
|
|
|
|
|
[14]
|
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery
Expert Opinion on Drug Delivery,
2021
DOI:10.1080/17425247.2021.1981286
|
|
|
|
|
[15]
|
Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Clinical Pharmacology in Drug Development,
2021
DOI:10.1002/cpdd.936
|
|
|
|
|
[16]
|
Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
PLOS ONE,
2020
DOI:10.1371/journal.pone.0227961
|
|
|
|
|
[17]
|
Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab
The Breast,
2020
DOI:10.1016/j.breast.2020.05.001
|
|
|
|
|
[18]
|
Reducing wait time for administration of systemic anticancer treatment (SACT) in a hospital outpatient facility
BMJ Open Quality,
2020
DOI:10.1136/bmjoq-2019-000904
|
|
|
|
|
[19]
|
Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Expert Review of Pharmacoeconomics & Outcomes Research,
2020
DOI:10.1080/14737167.2021.1860024
|
|
|
|
|
[20]
|
ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
Drug Delivery,
2019
DOI:10.1080/10717544.2018.1551442
|
|
|
|
|
[21]
|
Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden
PLOS ONE,
2019
DOI:10.1371/journal.pone.0211783
|
|
|
|
|
[22]
|
Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland
Clinical Breast Cancer,
2019
DOI:10.1016/j.clbc.2019.01.011
|
|
|
|
|
[23]
|
Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries
BioDrugs,
2019
DOI:10.1007/s40259-019-00359-0
|
|
|
|
|
[24]
|
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
European Journal of Obstetrics & Gynecology and Reproductive Biology,
2018
DOI:10.1016/j.ejogrb.2017.12.006
|
|
|
|
|
[25]
|
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
BioDrugs,
2018
DOI:10.1007/s40259-018-0295-0
|
|
|
|
|
[26]
|
Potential cost savings owing to the route of administration of oncology drugs
Anti-Cancer Drugs,
2018
DOI:10.1097/CAD.0000000000000648
|
|
|
|
|
[27]
|
VP07 Collaboratively Modelling The Impact Of Interventions Retrospectively
International Journal of Technology Assessment in Health Care,
2017
DOI:10.1017/S026646231700304X
|
|
|
|
|
[28]
|
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
The Breast,
2017
DOI:10.1016/j.breast.2017.05.004
|
|
|
|
|
[29]
|
Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
Clinical and Translational Oncology,
2017
DOI:10.1007/s12094-017-1684-4
|
|
|
|
|
[30]
|
Foreword
British Journal of Nursing,
2017
DOI:10.12968/bjon.2017.26.Sup16a.S3
|
|
|
|
|
[31]
|
Defining what matters most to patients
British Journal of Nursing,
2017
DOI:10.12968/bjon.2017.26.Sup16a.S15
|
|
|
|
|
[32]
|
Introduction
British Journal of Nursing,
2017
DOI:10.12968/bjon.2017.26.Sup16a.S4
|
|
|
|
|
[33]
|
Improving patient care: expert nursing and service development
British Journal of Nursing,
2017
DOI:10.12968/bjon.2017.26.Sup16a.S21
|
|
|
|
|
[34]
|
Current treatment of HER 2+ metastatic breast cancer
British Journal of Nursing,
2017
DOI:10.12968/bjon.2017.26.Sup16a.S7
|
|
|
|
|
[35]
|
Economic Analysis of Intravenous vs. Subcutaneously Administered Trastuzumab for the Treatment of HER2+ Early Breast Cancer in Malaysia
Advances in Breast Cancer Research,
2016
DOI:10.4236/abcr.2016.51001
|
|
|
|
|
[36]
|
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
European Journal of Cancer,
2016
DOI:10.1016/j.ejca.2016.03.087
|
|
|
|
|
[37]
|
Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting
The Breast,
2016
DOI:10.1016/j.breast.2016.07.008
|
|
|
|
|
[38]
|
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
PLOS ONE,
2016
DOI:10.1371/journal.pone.0157957
|
|
|
|
|
[39]
|
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom
Journal of Medical Economics,
2014
DOI:10.3111/13696998.2014.914033
|
|
|
|
|
[40]
|
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Annals of Oncology,
2014
DOI:10.1093/annonc/mdu364
|
|
|
|